Work

Phase I study of rilotumumab (AMG 102), an HGF inhibitor, and erlotinib in patients with advanced non-small cell lung cancer (NSCLC).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.e19065

Authors: Phu Tran, William E. Gooding, Liza Cosca Villaruz, Timothy Francis Burns, Mark A. Socinski, Ahmad A. Tarhini

Institutions: UPMC Hillman Cancer Center, University of Pittsburgh, University of Pittsburgh Medical Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2607278979

Cites:

Cited by: 3

Related to: 10